Inclisiran—Silencing the Cholesterol, Speaking up the Prognosis

Abstract excerpt

The reduction of circulating low-density lipoprotein-cholesterol (LDL-C) is a primary target in cardiovascular risk reduction due to its well-established benefits in terms of decreased mortality. Despite the use of statin therapy, 10%-20% of high- and very-high-risk patients do not reach their LDL-C targets. There is an urgent need for improved strategies to manage dyslipidemia, especially among patients with...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer, Lipids, and Metabolism
• Share to Diabetes, Cardiovascular Risks, and Lipoproteins
• Share to Lipoproteins and Cardiovascular Health